Bristol-Myers Squibb (BMY) Completes Inhibitex (INHX) Acquisition
Bristol-Myers Squibb Company (NYSE: BMY) announced today the successful completion of the tender offer by Bristol-Myers Squibb Company for all of the outstanding shares of common stock of Inhibitex, Inc. (Nasdaq: INHX) at a purchase price of $26.00 per share. As of the expiration of the offer, 77,532,611 shares of common stock of Inhibitex were validly tendered and not withdrawn in the tender offer. As of the close of business on February 10, 2012, approximately 4,260,705 shares remained subject to guaranteed delivery procedures.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Amylin (AMLN) Shares Jump as Bids Due Today, Sanofi (SNY), Merck (MRK) Said to Make First-Round Bids
- Facebook (FB) Could Boost Revs with This Potential Acquisition...
- Dollar Thrifty (DTG) Shares Spike Higher as Hertz (HTZ) Could Make an Offer
Create E-mail Alert Related Categories
Corporate News, Mergers and AcquisitionsRelated Entities
Bristol-Myers Squibb/InhibitexSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
